Reata Pharmaceuticals, Inc. RETA
172.36 0.00 (+0.00%)
At closeSep 25, 2023, 4:00 PM EDT
172.32 Day range 172.46
52-week range unavailable
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 115.30 -33.1% downside
Now 172.36
- Target (low)
- 85.00
- Target (mean)
- 115.30
- Target (high)
- 140.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy6
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 10
- 2 months ago 10
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -2.88 | -3.39 – -2.47 | -2.02 | -42.6% | 120.00K | -84.3% | 9 |
| Next quarter | -2.47 | -3.07 – -1.81 | -2.16 | -14.4% | 19.24M | +3463.0% | 9 |
| Current year | -10.47 | -12.15 – -8.43 | -8.54 | -22.6% | 54.33M | +2351.7% | 9 |
| Next year | -4.79 | -8.86 – -2.16 | -10.47 | +54.3% | 348.83M | +542.1% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 6, 2023 | TD Cowen | Initiated | — | Outperform |
| Jun 29, 2023 | Ladenburg Thalmann | Maintained | Buy | Buy |
| Jun 28, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Jun 28, 2023 | Barclays | Maintained | Overweight | Overweight |
| Jun 12, 2023 | SVB Leerink | Upgrade | Market Perform | Outperform |
| May 11, 2023 | Barclays | Maintained | Overweight | Overweight |
| Apr 13, 2023 | Stifel | Maintained | — | Buy |
| Mar 27, 2023 | Cantor Fitzgerald | Maintained | — | Overweight |
| Mar 1, 2023 | Baird | Maintained | — | Neutral |
| Mar 1, 2023 | Cantor Fitzgerald | Maintained | — | Overweight |
| Mar 1, 2023 | Citigroup | Maintained | — | Buy |
| Mar 1, 2023 | Goldman Sachs | Maintained | — | Buy |
| Mar 1, 2023 | Barclays | Maintained | — | Overweight |
| Feb 24, 2023 | Goldman Sachs | Maintained | — | Buy |
| Nov 28, 2022 | Goldman Sachs | Maintained | — | Buy |
| Nov 9, 2022 | Goldman Sachs | Maintained | — | Buy |
| Nov 9, 2022 | Citigroup | Maintained | — | Buy |
| Nov 9, 2022 | Barclays | Maintained | — | Overweight |
| Oct 19, 2022 | Guggenheim | Initiated | — | Buy |
| Aug 9, 2022 | Baird | Maintained | — | Neutral |
| May 27, 2022 | Citigroup | Maintained | — | Buy |
| May 24, 2022 | Goldman Sachs | Maintained | — | Buy |
| Mar 24, 2022 | Goldman Sachs | Upgrade | Neutral | Buy |
| Mar 1, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Dec 9, 2021 | Barclays | Maintained | — | Overweight |
| Dec 9, 2021 | Goldman Sachs | Downgrade | Buy | Neutral |
| Dec 9, 2021 | Barclays | Maintained | — | Overweight |
| Dec 9, 2021 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Dec 9, 2021 | Baird | Downgrade | Outperform | Neutral |
| May 24, 2021 | Goldman Sachs | Initiated | — | Buy |